Tag: Daniel O’Day
Gilead Sciences wraps up $4.9bn acquisition of Forty Seven
Gilead Sciences has completed its previously announced $4.9 billion acquisition of Forty Seven, a clinical-stage immuno-oncology company based in California. The immuno-oncology company has been ... Read More
Gilead Sciences to acquire immuno-oncology company Forty Seven for $4.9bn
Gilead Sciences acquisition of Forty Seven : US biotech company Gilead Sciences has signed an all-cash deal worth around $4.9 billion to acquire Forty Seven, ... Read More
Gilead Sciences bags Descovy FDA approval for prevention of HIV infection
Descovy FDA approval : Gilead Sciences’ Descovy (emtricitabine 200 mg and tenofovir alafenamide 25 mg tablets; F/TAF) has been approved by the US Food and ... Read More
Gilead Sciences names Lilly senior VP Christi L. Shaw as Kite CEO
US biopharma company Gilead Sciences has named Christi L. Shaw as the new chief executive officer of its subsidiary Kite, a California-based cell therapy company, ... Read More